# US 9,040,569 B2 · Compositions and methods for treating or preventing pneumovirus infection and associated diseases > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,040,569 B2 - Document ID: US9040569B2 - Status: Granted - Kind: B2 - Application number: 13/931,201 - Filed: 2013-06-28 - Published: 2014-01-02 - Granted: 2015-05-26 - Earliest claimed: 2012-06-29 - Assignees: Microdose Therapeutx, Inc. - Applicants: Microdose Therapeutx, Inc. - Inventors: Robert O. Cook; Eugene R. Reynolds; Boris Shekunov; Siead I. Zegar - Web page: https://patentgrep.com/patent/US9040569B2 ## CPC - A61K 31/41: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole - A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)} - A61P 11/00: Drugs for disorders of the respiratory system - A61P 11/02: Nasal agents, e.g. decongestants - A61P 27/16: Otologicals - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61P 31/12: Antivirals - A61P 31/14: for RNA viruses - C07D 257/04: Five-membered rings - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08) ## Abstract The present invention provides novel crystalline polymorphic forms of MDT-637, in particular, crystalline polymorphic forms with physicochemical properties specifically suited for drug production, amorphous formation, composite form, and methods of preparation thereof. The novel polymorphs described herein are useful for the treatment of respiratory disease, such as disease caused by respiratory syncytial virus. ## Claims ### Claim 1 A composition comprising at least one polymorph of MDT-637 selected from the group consisting of amorphous form, P-2 hydrate crystal form, P-3 dihydrate crystal form, P-3 ethanolate crystal form, P-3 monohydrate crystal form, P-3 anhydrous crystal form, P-2 anhydrous crystal form, P-4 crystal form, P-6 crystal form, P-7 crystal form, P-8 crystal form, and combinations thereof. ### Claim 2 (depends on 1) The composition of claim 1, additionally comprising one or more pharmaceutically acceptable carriers. ### Claim 3 (depends on 1) The composition of claim 1, wherein the at least one polymorph of MDT-637 comprises a crystal form of P-2 hydrate. ### Claim 4 (depends on 1) The composition of claim 1, wherein the at least one polymorph of MDT-637 comprises a crystal form of P-3 monohydrate. ### Claim 5 (depends on 1) The composition of claim 1, wherein the at least one polymorph of MDT-637 comprises a crystal form of P-3 dihydrate. ### Claim 6 (depends on 1) The composition of claim 1, wherein the at least one polymorph of MDT-637 comprises a crystal form of P-2 anhydrous. ### Claim 7 (depends on 1) The composition of claim 1, wherein the at least one polymorph of MDT-637 is a crystal form of P-3 anhydrous. ### Claim 8 (depends on 1) The composition of claim 1, wherein the at least one polymorph of MDT-637 is a crystal form of P-3 ethanolate. ### Claim 9 (depends on 1) The composition of claim 1, wherein the at least one polymorph of MDT-637 is selected from P-4 crystal form, P-6 crystal form, P-7 crystal form, or P-8 crystal form. ### Claim 10 (depends on 1) The composition of claim 1, wherein the at least one polymorph of MDT-637 is dispersed in at least one pharmaceutical excipient to provide a solid composite. ### Claim 11 A method of treating a subject having a disease resulting from infection by Paramyxovirinae or Pneumovirinae, comprising administering to the subject a compound in an amount effective to treat the subject wherein the compound comprises at least one polymorph of MDT-637 selected from the group consisting of amorphous form, P-2 hydrate crystal form, P-3 dihydrate crystal form, P-3 ethanolate crystal form P-3 monohydrate crystal form P-3 anhydrous crystal form P-2 anhydrous crystal form P-4 crystal form P-6 crystal form, P-7 crystal form, P-8 crystal form and combinations thereof. ### Claim 12 (depends on 11) The method of claim 11, wherein the at least one polymorph of MDT-637 is selected from P-2 hydrate crystal form, P-3 monohydrate crystal form and P-3 dihydrate crystal form. ### Claim 13 (depends on 11) The method of claim 11, wherein the method of treating the disease comprises alleviating and preventing symptoms associated with respiratory syncytial virus wherein the symptoms comprise rhinitis, otitis media, pneumonia and bronchiolitis. ### Claim 14 (depends on 11) The method of claim 11, wherein the compound is administered to the subject via inhalation. ### Claim 15 A method of treating a subject having an infection associated with respiratory syncytial virus, comprising administering to the subject a compound in an amount effective to treat the subject wherein the compound comprises eat least one polymorph of MDT-637 selected from the group consisting of amorphous form P-2 hydrate crystal form P-3 dihydrate crystal form, P-3 ethanolate crystal form, P-3 monohydrate crystal form, P-3 anhydrous crystal form, P-2 anhydrous crystal form, P-4 crystal form, P-6 crystal form, P-7 crystal form P-8 crystal form and combinations thereof.